In conclusion, targeting MFAP5highCAFs sensitizes pancreatic tumor to PD-L1-based immunochemotherapy via remodeling the desmoplastic and immunosuppressive TME (Fig. 7). This evidence concerns the gene CD274 and pancreatic neoplasm.